M&A Deal Summary

Sorrento Therapeutics Acquires Sherrington Pharmaceuticals

On October 9, 2013, Sorrento Therapeutics acquired life science company Sherrington Pharmaceuticals

Acquisition Highlights
  • This is Sorrento Therapeutics’ 2nd transaction in the Life Science sector.
  • This is Sorrento Therapeutics’ 2nd transaction in the United States.
  • This is Sorrento Therapeutics’ 1st transaction in New York.

M&A Deal Summary

Date 2013-10-09
Target Sherrington Pharmaceuticals
Sector Life Science
Buyer(s) Sorrento Therapeutics
Deal Type Add-on Acquisition

Target

Sherrington Pharmaceuticals

New York, New York, United States
Sherrington Pharmaceuticals, Inc. is a bio pharmaceutical company provides chronic and refractory pain treatment for end-stage cancer patients.

Search 177,534 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Sorrento Therapeutics

San Diego, California, United States

website


Category Company
Founded 2006
Sector Life Science
Employees502
Revenue 40M USD (2020)
DESCRIPTION

Sorrento Therapeutics is an oncology company that is involved in the development of small molecules, mono- and bi-specific antibodies and antibody drug conjugates for treatment of cancer and associated pain. Sorrento Therapeutics was founded in 2006 and is based in San Diego, California.


DEAL STATS #
Overall 2 of 9
Sector (Life Science) 2 of 9
Type (Add-on Acquisition) 2 of 7
State (New York) 1 of 1
Country (United States) 2 of 8
Year (2013) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2013-03-01 IgDraSol

Fountain Valley, California, United States

IgDraSol, Inc. is a pharamaceutal company focused on the development of oncologic agents for the treatment of metastatic breast cancer (“MBC”), non-small cell lung cancer (“NSCLC”), and other cancers.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-05-15 IgDraSol

Fountain Valley, California, United States

IgDraSol, Inc. is a pharamaceutal company focused on the development of oncologic agents for the treatment of metastatic breast cancer (“MBC”), non-small cell lung cancer (“NSCLC”), and other cancers.

Sell -